The economics of abiraterone acetate for castration-resistant prostate cancer

References

• Sorensen S, Ellis L, Wu Y, et al. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm 2013;19(9):799-808
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467-79
   PubMed Web of Science ®Google Scholar
• Vasani D, Josephson DY, Carmichael C, et al. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas 2011;70(2):194-6
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-8
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration- resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28(9):1481-8
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
   PubMed Web of Science ®Google Scholar
• Arrabal-Martín M, Anglada-Curado F, Cózar-Olmo JM, et al. Pre-chemotherapy abiraterone acetate. a proposal of a treatment algorithm in castration resistant prostate cancer. Actas Urol Esp 2013. [Epub ahead of print]
   Google Scholar
• Procopio G, Grassi P, Testa I, et al. Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am J Clin Oncol 2013. [Epub ahead of print]
   Google Scholar
• Zeliadt SB, Penson DF. Pharmacoeconomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics 2007;25(4):309-27
   PubMed Web of Science ®Google Scholar
• Piper NY, Kusada L, Lance R, et al. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis 2002;5(2):164-6
   Google Scholar
• Hatoum HT, Crawford ED, Nielsen SK, et al. Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res 2013;13(2):251-9
   Web of Science ®Google Scholar
• Hart W, Nazir J, Baskin-Bey E. An incidence model of the cost of advanced prostate cancer in Spain. J Med Econ 2014;17(2):125-31
   Google Scholar
• Ning YM, Pierce W, Maher VE, et al. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: u.s. Food and drug administration drug approval summary. Clin Cancer Res 2013;19(22):6067-73
   Google Scholar
• Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24(7):1802-7
   PubMed Web of Science ®Google Scholar
• Peer A, Gottfried M, Sinibaldi V, et al. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate 2014;74(4):433-40
   PubMed Web of Science ®Google Scholar
• Wilson L, Tang J, Zhong L, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Collins R, Fenwick E, Trowman R, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007;11(2):1-179
   Web of Science ®Google Scholar
• Zhong L, Pon V, Srinivas S, et al. Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: a Cost- Effectiveness Analysis. PLoS One 2013;22:8(5):e64275
   Google Scholar
• Dellis A, Papatsoris AG. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer. Expert Opin Biol Ther 2014;14(1):7-10
   PubMed Web of Science ®Google Scholar
• Carter JA, Joshi AD, Kaura S, Botteman MF. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Pharmacoeconomics 2012;30(5):373-86
   Google Scholar
• Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15(4):712-23
   PubMedGoogle Scholar